Wuhan Hiteck Biological Pharma Co.,Ltd.’s Net Profit Rose 328.5% in First Half of 2022

Wuhan Hiteck Biological Pharma Co.,Ltd. (武汉海特生物制药股份有限公司) (300683.SZ) reported a net profit of 25.3 million yuan in the first half of 2022, up 328.5% year-on-year.

Meanwhile, the company posted 387.2 million yuan in revenue, up 71.7% year-on-year.

At the end of the reporting period, it had 2.7 billion yuan in total assets and 326.4 million yuan in total liabilities, with a liability-to-asset ratio of 12.1%.